e-Therapeutics plc Director/PDMR Shareholding (4472Q)
20 Febrero 2023 - 4:19AM
UK Regulatory
TIDMETX
RNS Number : 4472Q
e-Therapeutics plc
20 February 2023
e-therapeutics plc
("e-therapeutics" or the "Company")
Director/PDMR Shareholding
London, UK, 20 February 2023 - e-therapeutics plc (AIM: ETX;
OTCQX; ETXPF), a company integrating computational power and
biological data to discover life-transforming RNAi medicines,
announces that Mr Ali Mortazavi, the Company's Chief Executive
Officer, has notified the Company of the transfer of 50,941,666
Ordinary Shares for nil consideration from TS Capital/JIM Nominees
Limited to WH Ireland/SEI Investments (Europe).
Mr Mortazavi's shareholding is unchanged at 50,941,666 Ordinary
Shares, representing 8.75% of the Company's total issued share
capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Ali Mortazavi
----------------------------------------- -----------------------------------------
2 Reason for the notification Transfer to new Nominee
------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
----------------------------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
----------------------------------------- -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------
a) Name e-therapeutics plc
----------------------------------------- -----------------------------------------
b) LEI 21380049RHSSJXWKYT18
----------------------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1 pence each
financial instrument,
type of instrument
Identification code ISIN: GB00B2823H99
b) Nature of the transaction Transfer of shares between broker
accounts. No change in beneficial
ownership.
----------------------------------------- -----------------------------------------
c) Price(s) and volume(s)
-------------- ----------------------
Price Volume
-------------- ----------------------
Nil 50,941,666
------------------------------------------------------------- ----------------------
d) Aggregated information N/A - single transaction
- Aggregated volume
- Price
e) Date of the transaction 20 February 2023
----------------------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------------------- -----------------------------------------
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)20 4551
James Chandler, VP IR & Communications 8888
www.etherapeutics.co.uk
------------------------------------------------ -------------------------
SP Angel Corporate Finance LLP Tel: +44(0)20 3470 0470
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
------------------------------------------------ -------------------------
About e-therapeutics plc www.etherapeutics.co.uk
e-therapeutics plc ("ETX") integrates computational power and
biology information to discover life-transforming RNAi medicines.
The Company's technology uses computation to capture and model
human biology, identify novel targets, and develop RNAi medicines
against those targets that can be rapidly progressed to the
clinic.
ETX's proprietary Computational Biology Platform enables the
generation and analysis of biological network models, providing a
novel and mechanistic approach to drug discovery that explicitly
considers the true complexity of biology and makes more reliable
predictions from large complex data sets and ETX's proprietary
hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data and information resource. The
Company generates, prioritises and tests millions of hypotheses in
silico to identify better therapeutic targets with higher
confidence.
ETX's proprietary RNAi Platform enables the targeted delivery to
hepatocytes in the liver and the specific silencing of novel
disease-associated genes, identified by ETX's Computational Biology
Platform. The focus on hepatocytes offers the opportunity to work
across a wide variety of diseases. The liver is a highly
metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of
action.
ETX is progressing a pipeline of first-in-class pre-clinical
RNAi candidates in several therapeutic areas including haematology,
cardiovascular disease and non-alcoholic steatohepatitis ("NASH").
ETX has also partnered with biopharma companies such as Novo
Nordisk, Galapagos NV and iTeos Therapeutics using its
computational network biology approach across a diverse range of
drug discovery projects.
The Company is based in London, UK and listed on the Alternative
Investment Market of the London Stock Exchange ("AIM"), with ticker
symbol ETX. e-therapeutics is also traded on the OTCQX Best Market
(OTCQX) in the United States, under ticker symbol ETXPF.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFLIFRIIFIV
(END) Dow Jones Newswires
February 20, 2023 05:19 ET (10:19 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De May 2023 a May 2024